CHEMOTHERAPY FOR ONCOLOGICAL DISEASES AND THE RISK OF DEVELOPING A CARDIOTOXIC PROFILE ON THE EXAMPLE OF THE HUMAN RECOMBINED MONOCLONAL ANTIBODY BEVACIZUMAB
Stanislav Valerievich Khlyamov,
Galina Sergeevna Mal,
Elena Borisovna Artyushkova,
Mikhail Petrovich Gladchenko Abstract
The detection and management of chemotherapy-associated oncological nosologies, cardiovascular toxicity, defined as either an acute cardiac event or a chronic condition, has been tightly integrated into routine oncology care and has become an important component in treatment selection. Some chemotherapeutic agents, such as anthracyclines, are traditionally characterized as cardiotoxic, but cardiovascular side effects are also associated with commonly used molecular targeted drugs. In the last decade, bevacizumab, a monoclonal humanized antibody against vascular endothelial growth factor, has been introduced in the treatment of various metastatic malignancies. Despite its efficacy, bevacizumab has been associated with a significant risk of cardiovascular events such as hypertension, cardiac ischemia, and congestive heart failure. The focus will be on the cardiovascular toxicity of bevacizumab, with the latest data on incidence, clinical spectrum, risk factors, and responsible mechanisms provided.
About the Authors
Stanislav Valerievich Khlyamov
Kursk State Medical University
Russian Federation
Russian Federation
Department of Pharmacology, Postgraduate Student
Galina Sergeevna Mal
Kursk State Medical University
Russian Federation
Russian Federation
Department of Pharmacology, Head of the Department of Pharmacology, Professor, Doctor of Medical Sciences
Elena Borisovna Artyushkova
Kursk State Medical University
Russian Federation
Russian Federation
Department of Pharmacology, Director of the Research Institute of Experimental Medicine, Associate Professor, Doctor of Biological Sciences
Mikhail Petrovich Gladchenko
Kursk State Medical University
Russian Federation
Russian Federation
Research Institute of Experimental Medicine, Senior Researcher, Candidate of Pharmaceutical Sciences
References
1. Cardiovascular complications of anticancer therapy: diagnosis, prevention, treatment / ed. I.E. Chazovoi, M.V. Viceni, F.T. Ageeva. - M.: GRANAT, 2019. - 160 p.
2. Chazova I.E., Ageev F.T., Aksenova A.V. [et al.] Eurasian Clinical Guidelines for the Diagnosis, Prevention and Treatment of Cardiovascular Complications in Anticancer Therapy (2022) // Eurasian Journal of Cardiology. - 2022. - No. 1. - P. 6-79.
3. Curigliano G., Lenihan D., Fradley M. [et al.] Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations // Annals of Oncology. - 2020. - Vol. 31. - № 2. - P. 171-190.
4. Dedong Cao, Yongfa Zheng, Huilin Xu [et al.] Bevacizumab improves survival in metastatic colorectal cancer patients with primary tumor resection: A meta-analysis // Nature. - 2019. - № 9. - P. 1-8.
5. Dent F.S. Practical cardio-oncology / F.S. Dent. - CRC Press, 2020. - 261 p.
6. Dobbin S.J.H., Mangion K., Berry C. [et al.] Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer // European Journal Heart Failure. - 2020. - №22. - P. 1276–1277.
7. Gilchrist S.C., Barac A., Ades P.A. [et al.] Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association // Circulation. - 2019. - №139. P. e997–e1012.
8. Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia // Nature Reviews Cardiology. - 2020. - №17. - P. 474–502.
9. Herrmann J. Vascular toxic effects of cancer therapies // Nature Reviews Cardiology. - 2020. - №17. - P. 503–522.
10. Herrmann J., Lenihan D., Armenian S. [et al.] Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement // European Heart Journal. - 2022. - №43. - P. 280-299.
11. Lancellotti P., Suter T.M., López-Fernández T. [et al.] Cardio-oncology services: rationale, organization, and implementation // European Heart Journal. - 2019. - №40. - P. 1756–1763.
12. Li M., Kroetz D.L. Bevacizumab-induced hypertension: clinical presentation and molecular understanding // Pharmacology & Therapeutics. - 2018. - Vol. 182. - № 2. - P. 152-160.
13. Lyon A.R., Dent S., Stanway S. [et al.] Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society // European Journal Heart Failure. - 2020. - №22. - P. 1945–1960.
14. Lyon A.R., López-Fernández T., Couch L.S. [et al.] 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) // European Heart Journal. - 2022. - №43(41). - P. 4229-4361.
15. Nhola L.F., Abdelmoneim S.S., Villarraga H.R. [et al.] Echocardiographic assessment for the detection of cardiotoxicity due to vascular endothelial growth factor inhibitor therapy in metastatic renal cell and colorectal cancers // Journal American Society Echocardiogrhy. - 2019. - №32. - P. 267–276.
16. Pandey A.K., Singhi E.K., Arroyo J.P. [et al.] Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease // Hypertension. - 2018. - №71. - P. E1–E8.
17. Ran Xu, Chen Xu, Chuntong Liu [et al.] Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer // OncoTargets and Therapy. - 2018. - № 11. - P. 8605-8621.
Review
For citations:
Khlyamov S.V., Mal G.S., Artyushkova E.B., Gladchenko M.P. CHEMOTHERAPY FOR ONCOLOGICAL DISEASES AND THE RISK OF DEVELOPING A CARDIOTOXIC PROFILE ON THE EXAMPLE OF THE HUMAN RECOMBINED MONOCLONAL ANTIBODY BEVACIZUMAB. Innova. 2023;9(1). (In Russ.)
Views:
256
Email this article 